News and Events
Stay informed about RECOVER’s Long COVID research by reading the latest news and participating in upcoming events.
Featured News Item
RECOVER at mid-year: 2026 progress and what’s ahead
In 2026 so far, RECOVER has published new research findings across nearly all its different studies and will soon be enrolling participants for the next phases of the adult observational study and clinical trials.
Feature
51 Results
51 Results
RECOVER to share clinical trial updates at July 2026 webinars
During 2 webinars, RECOVER researchers and leaders will discuss its clinical trial programs—RECOVER-CT and RECOVER-TLC, including clinical trial results to date and what it means to take part in a Long COVID clinical trial.
Feature
RECOVER-TLC to host next webinar July 16, 2026
NIH and FNIH leaders will provide an overview of the clinical trial process and updates on the status of RECOVER-TLC.
Announcement
RECOVER hub brings Long COVID research to rural, low-income communities
ISCORE, a RECOVER hub spanning 10 states and Puerto Rico, is bringing Long COVID studies to communities often underfunded in research, drawing on decades of HIV experience to tackle another new infectious disease.
Feature
RECOVER Research Update: June 2026
RECOVER scientists, study participants, and Representatives are working together to make new discoveries about Long COVID and how to diagnose, prevent, and treat its symptoms.
Research Update
RECOVER builds on current knowledge about symptoms affecting the lungs and heart
As RECOVER’s adult observational study moves to the next phase, researchers continue to explore the various causes of common Long COVID symptoms, such as difficulty breathing.
Feature
R3 Seminar Recap: Impact of Long COVID on neurocognitive function
At the RECOVER Research Review (R3) Seminar held on April 14, RECOVER researchers presented findings on how Long COVID affects the brain, including difficulties with thinking clearly, memory, and concentration. They also outlined future research opportunities to better understand neurocognitive symptoms and how other body systems impact brain health.
R3 Seminar Recap
RECOVER-TLC announces public comment period for upcoming clinical trial
Patients, caregivers, and researchers will have 2 weeks to provide input on plans to test whether glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can help improve Long COVID symptoms.
Announcement
RECOVER continues to focus on understanding symptoms that affect the brain
RECOVER researchers are continuing plans to explore cognitive symptoms like brain fog in the initiative’s adult observational study, one of the most common but least understood symptoms of Long COVID.
Feature